V
Vincent Zoete
Researcher at Swiss Institute of Bioinformatics
Publications - 155
Citations - 20005
Vincent Zoete is an academic researcher from Swiss Institute of Bioinformatics. The author has contributed to research in topics: T-cell receptor & T cell. The author has an hindex of 43, co-authored 135 publications receiving 12342 citations. Previous affiliations of Vincent Zoete include Ludwig Institute for Cancer Research & University of Lausanne.
Papers
More filters
Journal ArticleDOI
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.
Jaikumar Duraiswamy,Riccardo Turrini,Aspram Minasyan,David Barras,Isaac Crespo,Alizée J. Grimm,Julia Casado,Raphael Genolet,Fabrizio Benedetti,Alexandre Wicky,Kalliopi Ioannidou,Wilson Castro,Christopher Neal,Amandine Moriot,Stephanie Renaud-Tissot,Victor Anstett,Noémie Fahr,Janos L. Tanyi,Monika A. Eiva,Connor A. Jacobson,Kathleen T. Montone,Marie Christine Wulff Westergaard,Inge Marie Svane,Lana E. Kandalaft,Mauro Delorenzi,Peter K. Sorger,Anniina Färkkilä,Olivier Michielin,Vincent Zoete,Santiago J. Carmona,Periklis G. Foukas,Daniel J. Powell,Sylvie Rusakiewicz,Marie-Agnès Doucey,Denarda Dangaj Laniti,George Coukos +35 more
TL;DR: The mechanisms regulating exhaustion of tumor-infiltrating lymphocytes (TIL) and responsiveness to PD-1 blockade remain partly unknown in human ovarian cancer, and as mentioned in this paper showed that tumor-specific CD8+ TIL accumulate in tumor islets, where they engage antigen and upregulate PD1, which restrains their functions.
Posted ContentDOI
The actin assembly requirements of the formin Fus1 to build the fusion focus
Ingrid Billault-Chaumartin,Laetitia Michon,Caitlin Anderson,Sarah Yde,Cristian Suarez,Justyna Iwaszkiewicz,Vincent Zoete,David R. Kovar,Sophie G. Martin +8 more
TL;DR: It is established that changes in formin nucleation and elongation rates have direct consequences on the architecture of the fusion focus, and that Fus1 native high nucleations and low elongations rates are optimal for fusion focus assembly.
Journal ArticleDOI
Identification de nouveaux gènes impliqués dans les carcinomes basocellulaires sporadiques
Laurent Parmentier,Ximena Bonilla,Bryan W. King,Fedor Bezrukov,Gürkan Kaya,Vincent Zoete,Vladimir B. Seplyarskiy,Hayley J. Sharpe,Thomas Alexander Mckee,Audrey Letourneau,Pascale Ribaux,K. Papodin,Nicole Basset-Seguin,R. Ben Chaabene,Federico Santoni,Michel Guipponi,Maria A. Andrianova,Marco Garieri,C. Verdan,K. Grosdemange,Olga Sumara,Martin Eilers,Iannis Aifantis,Olivier Michielin,F. de Sauvage,Stylianos E. Antonarakis,Sergey Nikolaev +26 more
TL;DR: Le taux moyen de mutations pour les BCC etait de 65/Mb, soit le chiffre le plus eleve de tous les cancers humains, while l’ADN controle etait obtenu sur sang peripherique dans 90 % des cas.
Journal ArticleDOI
FOXI3 pathogenic variants cause one form of craniofacial microsomia
Ke Mao,Christelle Borel,Muhammad Ansar,Angad Jolly,Periklis Makrythanasis,Christine Froehlich,Justyna Iwaszkiewicz,Bingqing Wang,Xiaopeng Xu,Qiang Li,Xavier Blanc,Qi Chen,Fujun Jin,Harinarayana Ankamreddy,Sunita Singh,Xiaogang Wang,Pei-Jen Chen,Emmanuelle Ranza,Sohail A. Paracha,Syed Fahim Shah,Valentina Guida,Francesca Piceci-Sparascio,Daniela Melis,C. Dallapiccola,Maria Cristina Digilio,Antonio Novelli,Monia Magliozzi,Maria Teresa Fadda,Haley Streff,Keren Machol,Richard A. Lewis,Vincent Zoete,Gabriella Maria Squeo,Paolo Prontera,Giorgia Mancano,Giulia Gori,Milena Mariani,Angelo Selicorni,Stavroula Psoni,Helen Fryssira,Sofia Douzgou,Sandrine Marlin,Saskia Biskup,A. De Luca,Giuseppe Merla,Shouqin Zhao,Timothy C. Cox,Andrew K. Groves,James R. Lupski,Qingguo Zhang,Yongbiao Zhang,Stylianos E. Antonarakis +51 more
TL;DR: In this article , the authors identify 18 likely pathogenic variants in 21 probands (3.1%) in FOXI3 and provide suggestive evidence that common variation in the FoxI3 allele in trans with the pathogenic variant could modify the phenotypic severity and accounts for the incomplete penetrance.
Patent
Kinase mutants and uses thereof
Olivier Michielin,Vincent Zoete,George Coukos,Melita Irving,Nahzli Dilek,Patrick Reichenbach,Kelly Ascencao +6 more
TL;DR: In this article, the present invention relates to methods of designing kinase mutants for reprogramming the sensitivity of a target kinase to some specific inhibitors, wherein those kinase inhibitors have little or no affinity for the wild-type target Kinase, vectors or cells expressing said mutated kinases, composition and uses thereof for the prevention and/or treatment of a disease or disorder, in particular cancer.